TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Precigen ( (PGEN) ) has shared an update.
On August 13, 2025, Precigen, Inc. entered into a Commercial Supply Agreement with Catalent Maryland, Inc. This agreement mandates Catalent to provide various services including analytical, development, processing, validation, and product maintenance for Precigen’s product, PAPIZEMOS. The agreement establishes Catalent as the exclusive provider for Precigen’s commercial fill and finish manufacturing needs for PAPIZEMOS, with terms including annual price adjustments and a minimum purchase requirement. The initial term of the agreement is three years, with automatic one-year renewals unless terminated by either party. This collaboration is expected to streamline Precigen’s manufacturing processes and potentially enhance its market positioning by ensuring consistent product supply.
The most recent analyst rating on (PGEN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Precigen stock, see the PGEN Stock Forecast page.
Spark’s Take on PGEN Stock
According to Spark, TipRanks’ AI Analyst, PGEN is a Neutral.
Precigen’s overall stock score reflects a balance between strong technical momentum and positive corporate events against a backdrop of weak financial performance and concerning valuation metrics. The FDA approval is a significant positive, but financial instability remains a major risk.
To see Spark’s full report on PGEN stock, click here.
More about Precigen
Precigen, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative gene and cell therapies.
Average Trading Volume: 5,164,658
Technical Sentiment Signal: Buy
Current Market Cap: $876M
For an in-depth examination of PGEN stock, go to TipRanks’ Overview page.